

Boehringer Ingelheim Pharmaceuticals, Inc. 900 Ridgebury Road Ridgefield, CT 06877

May 12, 2025

Notice to 340B Covered Entities in the state of Tennessee Update to Boehringer Ingelheim Contract Pharmacy Policy Effective May 30, 2025

Dear 340B Covered Entity:

I am writing to inform you that Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer) is updating its 340B Program contract pharmacy policies effective May 30, 2025 for drugs dispensed by covered entities within the state of Tennessee on or after that date.

Boehringer will require the submission of claims data for 340B utilization filled by covered entities in-house pharmacies. All specified claims must be submitted on the 340B ESP[™] platform within 45 days of the date of dispense.

If you have any questions regarding Boehringer Ingelheim's updated 340B Program contract pharmacy policy in the state of Tennessee, please reach out to support@340besp.com.

Best Regards,

Signed by: Brian Hilberdink D55CC6053D1E443

Brian Hilberdink President U.S. Human Pharma Boehringer Ingelheim Pharmaceuticals, Inc.

DocuSigned by: Christine Marsh 20828F4D4469469

Christine Marsh Senior Vice President, Value and Access Boehringer Ingelheim Pharmaceuticals, Inc.